Frank Seebach

4.0k citations

37 papers · 407 indexed · h-index 9

Impact in

Critical Care and Intensive Care Medicine top 5%
- Trauma, Hemostasis, Coagulopathy, Resuscitation
Hepatology top 10%
- Liver Disease and Transplantation

Papers in

Oncology 26
- Cancer Immunotherapy and Biomarkers 13
- CAR-T cell therapy research 10
Hepatology 5

Co-authors: Michael Kashgarian Christian Sitzwohl Michael Felfernig Alex M. Blaicher C. Gonano M. Zimpfer Norman J. Siegel Scott K. Van Why
Journals: Journal of Clinical Oncology (16 papers)Annals of Oncology (5 papers)Journal of Thoracic Oncology (2 papers)American Journal of Physiology-Renal Physiology (2 papers)Anesthesia & Analgesia (2 papers)
Partner nations: United States Australia Germany

In The Last Decade

Frank Seebach

34 papers receiving 397 citations

Peers

Countries citing papers authored by Frank Seebach

Since Specialization

Citations

This map shows the geographic impact of Frank Seebach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Seebach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Seebach more than expected).

Fields of papers citing papers by Frank Seebach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Seebach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Seebach. The network helps show where Frank Seebach may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Frank Seebach, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frank Seebach Line = papers co-authored together Frank Seebach links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1605MO Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1 relapsed/refractory melanoma Annals of Oncology ·Keizo Miyashita, Stephan Grabbe, Michele Guida, Marina Cara, V. Bühren, W. C. Rusty Riese, Janet L. Markman, Runcheng Wuzhao, Hushan Yang, Katarina Ćuk, Cintya Neves de Souza, P. A. Lee, Pascal Omombo Kiyonge, Michael J. Wenger, Dobrev Ivan, Frank Seebach, D. Yu. Gritsevskaya, Kong XiangJin, Uğur Şahin, C. Parrondo	2025	0
2	A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology ·Bilal A. Siddiqui, Benedito A. Carneiro, Mark N. Stein, Jingsong Zhang, William Kevin Kelly, David R. Wise, Katarina A. Milas, Gerald S. Falchook, Przemyslaw Twardowski, Xīn Gào, Joseph W. Kim, Edward P. Gelmann, Pradeep Thanigaimani, Fang Fang, Frank Seebach, Israel Lowy, Matthew Ingham, Michael D. Kinnaman, 実松太, Elizabeth Miller	2025	1
3	Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·William Kevin Kelly, Sandy Srinivas, Joseph Maly, Deepak Kilari, Arif Hussain, Biren Saraiya, Bilal A. Siddiqui, Paul Monk, Gurkamal Chatta, Vivek Narayan, Divya Rana, Pradeep Thanigaimani, Fang Fang, Dimitris Skokos, Jessica R. Kirshner, Frank Seebach, Israel Lowy, Matthew Ingham, 実松太, Elizabeth Miller	2025	1
4	Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial Lung Cancer ·柴田顗秀, Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, 盖美, Konstantin Penkov, К. К. Лактионов, 晁剑, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka‐Warzocha, Огородникова Надежда Петровна, Javier J. Pérez, Manika Kaul, Ruben G.W. Quek, Frank Seebach, Petra Rietschel, Jean‐François Pouliot	2024	4
5	A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results. Journal of Clinical Oncology ·Neil H. Segal, Eugenia Girda, Davendra Sohal, Nehal J. Lakhani, Anthony J. Olszanski, Lawrence Fong, Michael D. Kinnaman, Hyunsil Han, Dimitris Skokos, Kerry A. Casey, Luis Zamarioli, Bei Wang, Yi Hao, Siyu Li, Samit Ganguly, Israel Lowy, Frank Seebach, Melissa Mathias, Melissa L. Johnson	2024	5
6	Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices Cancer Management and Research ·Wenzhen Ge, Ning Wu, Chieh-I Chen, 栄三稲垣, Iqlima Rahmawati, Frank Seebach, Matthew G. Fury, James Harnett, 明文大下	2024	1
7	Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials. Journal of Clinical Oncology ·Joseph C. Murray, Огородникова Надежда Петровна, Valsamo Anagnostou, Julie R. Brahmer, Alexander Meisel, Ahmet Sezer, Miranda Gogishvili, Tamar Melkadze, 柴田顗秀, Tamta Makharadze, Francesc Riart, Siyu Li, Vladimir Janković, Frank Seebach, Petra Rietschel, Young J. Kim, Giuseppe Gullo, Jean‐François Pouliot	2023	1
8	A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update. Journal of Clinical Oncology ·Neil H. Segal, Soroka Baker, Eugenia Girda, Lawrence Fong, Anthony J. Olszanski, Hyunsil Han, Kerry A. Casey, Siyu Li, Erik S. Welf, Chieh-I Chen, Dimitris Skokos, Frank Seebach, Israel Lowy, Matthew G. Fury, Melissa Mathias, Nehal J. Lakhani	2023	5
9	1885P Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTI-PD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II study Annals of Oncology ·Sun Young Rha, Woo Kyun Bae, Pelissari, Lucas Barbosa, 1987-, Sung Yong Oh, Hyun Woo Lee, Maximilian Riegel, Nataliya Mar, Ganessan Kichenadasse, Hong Koo Ha, Russell K. Pachynski, Inkeun Park, Alexander Baker, Dilmurod Tashev, Edmund Folefac, Melissa Mathias, Frank Seebach, Mohammad Ali Shokrgozar, Javier Mauricio González, Jae Shin Choi, Jaime R. Merchan	2023	1
10	Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3 SKIN The Journal of Cutaneous Medicine ·Michael R. Migden, Chrysalyne D. Schmults, Nikhil I. Khushalani, Alexander Guminski, Anne Lynn S. Chang, Karl D. Lewis, George Ansstas, Samantha Bowyer, Brett Hughes, Dirk Schadendorf, Badri Modi, Lara Dunn, Lukas Flatz, Axel Hauschild, Suk‐Young Yoo, Jocelyn Booth, Frank Seebach, Israel Lowy, Matthew G. Fury, Danny Rischin	2023	1
11	Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial Journal of Thoracic Oncology ·Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, 柴田顗秀, 盖美, Konstantin Penkov, К. К. Лактионов, 晁剑, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka‐Warzocha, Siyu Li, Yuntong Li, Manika Kaul, Ruben G.W. Quek, Jean‐François Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel	2023	39
12	LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial Annals of Oncology ·Mustafa Özgüroğlu, Saadettin Kılıçkap, Rāmacandra Pāṭhaka, (unknown), Igor Bondarenko, Dmytro Sagaidachny, Marina Nechaeva, Violetta Lien, (unknown), Gwo Fuang Ho, Lynette Elford, Mikhail Dvorkin, EV Raghava Rao, Fersan A. Sallam, Craig R. Kuchel, М. С. Шманатов, Frank Seebach, Patxi Lascurain-Ibarlucea, Fouad Hadj‐Selem, Petra Rietschel	2022	7
13	735 A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: initial dose-escalation results Regular and Young Investigator Award Abstracts ·Melissa M. Johnson, Nehal J. Lakhani, Eugenia Girda, Anthony J. Olszanski, Lawrence Fong, Hyunsil Han, Kerry A. Casey, Siyu Li, Jennifer Visich, F FURTMUELLER, Frank Seebach, Israel Lowy, Matthew G. Fury, Melissa Mathias, Neil H. Segal	2022	2
14	A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology ·Jingsong Zhang, Mark N. Stein, William Kevin Kelly, Che‐Kai Tsao, Gerald S. Falchook, R. Batterson, Frank Seebach, Israel Lowy, Kosalai Kal Mohan, Glenn S. Kroog, Elizabeth Miller	2021	8
15	Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis. Journal of Clinical Oncology ·Mustafa Özgüroğlu, Ahmet Sezer, Saadettin Kılıçkap, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Hacı Mehmet Türk, İrfan Çiçin, Dmitry Bentsion, Oleg Gladkov, Philip R. Clingan, Virote Sriuranpong, Naiyer A. Rizvi, Jennifer McGinniss, Jean‐François Pouliot, Sue Lee, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel	2021	8
16	A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology ·Charles G. Drake, Jingsong Zhang, Mark N. Stein, R. Batterson, Frank Seebach, Israel Lowy, Kosalai Kal Mohan, Glenn S. Kroog, Elizabeth Miller	2020	4
17	Functional Activation of Heat Shock Factor and Hypoxia-Inducible Factor in the Kidney Journal of the American Society of Nephrology ·Oliver Eickelberg, Frank Seebach, Michael Riordan, Gunilla Thulin, Andrea Mann, Laura J. Sommerville, Scott K. Van Why, Michael Kashgarian, Norman J. Siegel	2002	50
18	K⁺-induced HSP-72 expression is mediated via rapid Ca²⁺influx in renal epithelial cells American Journal of Physiology-Renal Physiology ·Oliver Eickelberg, John P. Geibel, Frank Seebach, Gerhard Giebisch, Michael Kashgarian	2001	6
19	Thresholds for cellular disruption and activation of the stress response in renal epithelia American Journal of Physiology-Renal Physiology ·Scott K. Van Why, Sunmi Kim, John P. Geibel, Frank Seebach, Michael Kashgarian, Norman J. Siegel	1999	33
20	Endogenous Heparin-Like Substances Significantly Impair Coagulation in Patients Undergoing Orthotopic Liver Transplantation Anesthesia & Analgesia ·Stephan C. Kettner, C. Gonano, Frank Seebach, Christian Sitzwohl, E. Liimatainen, Maria Antonia Macedo Franco, Fr. De La Barra, Alex M. Blaicher, Michael Felfernig, M. Zimpfer	1998	66

About Frank Seebach

Frank Seebach is a scholar working on Oncology, Hepatology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Critical Care and Intensive Care Medicine, having authored 37 papers that have together received 407 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), CAR-T cell therapy research (10 papers), Lung Cancer Treatments and Mutations (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Nonmelanoma Skin Cancer Studies (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Prostate Cancer Treatment and Research (5 papers) and Virus-based gene therapy research (3 papers). The work is most often cited by research in Critical Care and Intensive Care Medicine (67 citations), Hepatology (64 citations), Oncology (166 citations), Hematology (64 citations) and Internal Medicine (15 citations). Frank Seebach has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Michael Kashgarian, Christian Sitzwohl, Michael Felfernig, Alex M. Blaicher, C. Gonano, M. Zimpfer, Norman J. Siegel, Scott K. Van Why, Stephan C. Kettner and Israel Lowy. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, American Journal of Physiology-Renal Physiology and Anesthesia & Analgesia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact